Who are Alpharix® Tetra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Spikevax bivalent Original/Omicron BA.1, BNT162b2 Pfizer-BioNTech/Comirnaty, BNT162b2 (Omi KP.2), BNT162b2 BA.4/5 bivalent, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, BNT162b2 (Omi XBB.1.5).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alpharix-tetra.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Alpharix® Tetra — Competitive Intelligence Brief

Alpharix® Tetra (Alpharix® Tetra) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease or Oncology.

phase 3 mRNA vaccine Immunology / Infectious Disease or Oncology Biologic Live · refreshed every 30 min

Target snapshot

Alpharix® Tetra (Alpharix® Tetra) — ModernaTX, Inc.. Alpharix Tetra is a multivalent mRNA vaccine designed to stimulate immune responses against multiple disease targets simultaneously.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Alpharix® Tetra TARGET	Alpharix® Tetra	ModernaTX, Inc.	phase 3	mRNA vaccine
Spikevax bivalent Original/Omicron BA.1	Spikevax bivalent Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
BNT162b2 Pfizer-BioNTech/Comirnaty	BNT162b2 Pfizer-BioNTech/Comirnaty	KK Women's and Children's Hospital	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
BNT162b2 (Omi KP.2)	bnt162b2-omi-kp-2	Pfizer Inc.	marketed	mRNA vaccine	Spike protein of SARS-CoV-2
BNT162b2 BA.4/5 bivalent	bnt162b2-ba-4-5-bivalent	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 virus
Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose	variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose	Pfizer	marketed	mRNA vaccine	SARS-CoV-2
BNT162b2 (Omi XBB.1.5)	bnt162b2-omi-xbb-1-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alpharix® Tetra — Competitive Intelligence Brief. https://druglandscape.com/ci/alpharix-tetra. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab